Entity
RelA-p65
--
MO000000193
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m166
10
infinite
0
TRANSPATH | MO000000193 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
p50:RelA-p65
--
MO000016632
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1617
10
infinite
0
TRANSPATH | MO000016632 |
--
CXCR3
--
MO000019843
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m4372
10
infinite
0
InterPro | IPR000276 |
TRANSPATH | MO000019843 |
--
SUMO-1
--
MO000019971
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m4499
10
infinite
0
InterPro | IPR000626 |
TRANSPATH | MO000019971 |
--
Ubc9
--
MO000019972
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m4500
10
infinite
0
TRANSPATH | MO000019972 |
--
glucocorticoids
--
MO000021732
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m6069
10
infinite
0
TRANSPATH | MO000021732 |
--
HDAC4
--
MO000042976
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m20760
10
infinite
0
TRANSPATH | MO000042976 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
CXCL1
--
e10
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m10
0
infinite
0
--
csml-variable:Double
m11
0
infinite
0
--
PPAR-alpha:RXR:PPRE
--
e12
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m12
0
infinite
0
--
Troglitazone
--
e13
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m13
0
infinite
0
--
PPAR-gamma
--
e14
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m14
0
infinite
0
--
PPAR-gamma:Troglitazone
--
e15
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m15
0
infinite
0
--
GW0742
--
e16
cso30:c:SmallMolecule
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m16
0
infinite
0
--
PPAR-delta
--
e17
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m17
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1
--
e18
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m18
0
infinite
0
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
LPS:TLR4
--
e20
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m20
0
infinite
0
--
p50:RelA-p65:IkappaB
--
e21
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m21
0
infinite
0
--
p50:RelA-p65:IkappaB{active}
--
e22
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m22
0
infinite
0
--
Degradants
--
e23
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m23
0
infinite
0
--
19s proteosome
--
e25
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m25
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1{ub}
--
e26
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m26
0
infinite
0
--
proteosome degradants
--
e27
cso30:c:EntityBiological
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m27
0
infinite
0
--
csml-variable:Double
m28
0
infinite
0
--
Activator complex
--
e29
cso30:c:Complex
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
p50:RelA-p65:iNOS:Activator complex
--
e30
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m30
0
infinite
0
--
PPAR-gamma:troglitazone:SUMO-1
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m31
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1:PPAR-gamma:Troglitazone:SUMO-1
--
e32
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m32
0
infinite
0
--
PPAR-gamma:RCXR
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m33
0
infinite
0
--
Inflammatory response gene mRNA
--
e34
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m34
0
infinite
0
--
RelA-p65:PPAR-alpha
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m35
0
infinite
0
--
PPARdelta:BCL-6
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
PPARdelta:GW0742
--
e37
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m37
0
infinite
0
--
LXRalpha
--
e38
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m38
0
infinite
0
--
LXRbeta
--
e39
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
Ligand
--
e40
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m40
0
infinite
0
--
LXRalpha:Ligand
--
e41
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m41
0
infinite
0
--
LXRbeta:Ligand
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m42
0
infinite
0
--
SUMO-2
--
e43
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m43
0
infinite
0
--
SUMO-3
--
e44
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m44
0
infinite
0
--
LXRalpha:ligand:SUMO-2:SUMo-3
--
e45
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m45
0
infinite
0
--
LXRalpha:ligand:SUMO-2:SUMo-3:NCor co-repressor complex
--
e46
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m46
0
infinite
0
--
LXRbeta:ligand:SUMO-2:SUMo-3
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m47
0
infinite
0
--
LXRbeta:ligand:SUMO-2:SUMo-3:NCor co-repressor complex
--
e48
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m48
0
infinite
0
--
GR ligand
--
e49
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m49
0
infinite
0
--
PPAR-alpha
--
e5
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
PPAR-alpha:RXR
--
e6
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
Glucocorticoids:GR ligand
--
e63
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
Glucocorticoids:GRligand:RelA-p65
--
e64
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m64
0
infinite
0
--
IL-8
--
e65
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m65
0
infinite
0
--
c-Jun:PPAR-alpha
--
e66
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m67
0
infinite
0
--
IL-12
--
e67
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m68
0
infinite
0
--
CXCL10
--
e68
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m69
0
infinite
0
--
Fenofibrate
--
e69
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m70
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
PPAR-alpha:Fenofibrate
--
e70
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m71
0
infinite
0
--
Wy14643
--
e71
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m72
0
infinite
0
--
PPARalpha:Wy14643
--
e72
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m73
0
infinite
0
--
IL-17
--
e73
cso30:c:SmallMolecule
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m74
0
infinite
0
--
ICAM-2
--
e74
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m75
0
infinite
0
--
CXCL8
--
e75
cso30:c:mRNA
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m76
0
infinite
0
--
GW7647
--
e76
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m77
0
infinite
0
--
PPARgamma:GW7845
--
e77
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m78
0
infinite
0
--
CXCL9
--
e78
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m79
0
infinite
0
--
CCL2
--
e79
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m80
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
CCL4
--
e80
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m81
0
infinite
0
--
CCL7
--
e81
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m82
0
infinite
0
--
CCl12
--
e82
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m83
0
infinite
0
--
CCL17
--
e83
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m84
0
infinite
0
--
CCL19
--
e84
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m85
0
infinite
0
--
GW7647
--
e85
cso30:c:SmallMolecule
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m86
0
infinite
0
--
PPAR-alpha:GW7647
--
e86
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m87
0
infinite
0
--
CXCL10:CXCR3
--
e87
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m88
0
infinite
0
--
CXCL9
--
e88
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m89
0
infinite
0
--
CXCL9:CXCR3
--
e89
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m90
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
CXCL11
--
e90
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m91
0
infinite
0
--
CXCL11
--
e91
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m92
0
infinite
0
--
CXCL11:CXCR3
--
e92
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m93
0
infinite
0
--
ROS
--
e93
cso30:c:SmallMolecule
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m94
0
infinite
0
--
PPARgamma
--
e94
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m95
0
infinite
0
--
PPAR-delta:ERK5
--
e95
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m96
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c2 : 1
stoichiometry:c1 : 1
stoichiometry:c3 : 1
m2283*m5*0.1
nodelay
--
0
PMID: 17981503,15629253,15860371 They form heterodimers with the retinoid X receptor (RXR) and activate transcription by binding to a specific DNA element termed the PPAR response element (PPRE)
p10
p10
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c25 : 1
stoichiometry:c26 : 1
m22*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c27 : 1
stoichiometry:c28 : 1
m1617*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c30 : 1
stoichiometry:c31 : 1
stoichiometry:c32 : 1
m18*m25*0.1
nodelay
--
0
PMID: 17981503 Concomitant with these events, the corepressor complex is ubiquitinated and degraded by the 19 S proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c34 : 1
m26*0.1
nodelay
--
0
PMID: 17981503 Concomitant with these events, the corepressor complex is ubiquitinated and degraded by the 19 S proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c36 : 1
stoichiometry:c37 : 1
m24*m19*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m29*m28*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m30*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m31*m18*0.1
nodelay
--
0
PMID: 17981503,16127449 The SUMOylated PPARgamma binds to NCoR and interferes with clearance of the corepressor complex, thereby maintaining the promoter in the repressed state
p18
p18
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c46 : 1
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c45 : 1
m4499*m15*m20*m4500*m2460*0.1
nodelay
--
0
PMID: 17981503 In cells treated with PPARgamma ligand plus LPS, ligand binding triggers conjugation of a small fraction of cellular PPARgamma with SUMO1 (small ubiquitin-like modifier) on lysine 365 (K365), mediated by the SUMOylation pathway E2 ligase Ubc9 and E3 ligase PIAS1 PMID: 17981503 Figure 2
p19
p19
cso30:i:ME_Binding
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c55 : 1
stoichiometry:c54 : 1
m14*m2283*0.1
nodelay
--
0
PMID: 17981503 SUMOylation of PPARgamma is predicted to prevent its heterodimerization with RXR, thereby dedicating this form of PPARgamma to a repressor function.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m2283*m11*0.1
nodelay
--
0
PMID: 17981503, 15629253, 15860371 They form heterodimers with the retinoid X receptor (RXR) and activate transcription by binding to a specific DNA element termed the PPAR response element (PPRE)
p20
p20
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c67 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12970571 Binding of ligand to PPARdelta releases BCL-6, which then represses inflammatory-response genes PMID: 17981503,17218271 The liver X receptors (LXRalpha and -beta) repress a subset of inflammatory-response genes that overlaps with, yet is distinct from, the subset repressed by PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m166*m5*0.1
nodelay
--
0
PMID: 17981503,10542237 Direct binding of PPARalpha to NF-KappaB p65 was demonstrated by in vitro assays, suggesting that transrepression might involve direct interference with transcriptional activation by NF-KappaB
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c60 : 1
stoichiometry:c61 : 1
m13276*m17*0.1
nodelay
--
0
PMID: 17981503 For PPARdelta, a novel mechanism for transrepression was identified that involves binding and sequestration of the transcriptional repressor BCL-6 by unliganded PPARdelta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
stoichiometry:c65 : 1
m36*m16*0.1
nodelay
--
0
PMID: 17981503,12970571 Binding of ligand to PPARdelta releases BCL-6, which then represses inflammatory-response genes
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c71 : 1
stoichiometry:c72 : 1
m38*m40*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m40*m39*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3.
p26
p26
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
stoichiometry:c78 : 1
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m41*m43*m44*m4500*m20760*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3 PMID: 17981503 Here, the E3 ligase is HDAC4 rather than PIAS1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c83 : 1
stoichiometry:c84 : 1
m45*m18*0.1
nodelay
--
0
PMID: 17981503 As with PPARgamma, SUMOylated LXR interferes with clearance of NCoR-containing corepressor complexes from the promoters of target genes.
p26
p28
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c87 : 1
stoichiometry:c88 : 1
stoichiometry:c89 : 1
stoichiometry:c90 : 1
m42*m44*m43*m20760*m4500*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3 PMID: 17981503 Here, the E3 ligase is HDAC4 rather than PIAS1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c92 : 1
stoichiometry:c93 : 1
m47*m18*0.1
nodelay
--
0
PMID: 17981503 As with PPARgamma, SUMOylated LXR interferes with clearance of NCoR-containing corepressor complexes from the promoters of target genes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m13*m14*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPAR¦Ã ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPAR¦Ä ligand GW0742 worsened the course of colitis in IL-10-deficient mice
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c99 : 1
m49*m6069*0.1
nodelay
--
0
PMID: 17981503,16127449,17072333 Ligand-bound GR interacts strongly with the p65 subunit of NF-KappaB, in contrast to ligand-bound PPARgamma, which interacts very weakly with p65
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m166*m63*0.1
nodelay
--
0
PMID: 17981503,16127449,17072333 Ligand-bound GR interacts strongly with the p65 subunit of NF-KappaB, in contrast to ligand-bound PPARgamma, which interacts very weakly with p65
p32
p32
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c102 : 1
stoichiometry:c103 : 1
stoichiometry:c101 : 1
m175*m24*0.1
nodelay
--
0
PMID: 17981503,15879558 Interestingly, repression by GR of tumor necrosis factor (TNF)-stimulated gene transcription in A549 lung adenocarcinoma cells is also target-gene specific: some NF-KappaB-dependent genes such as IL-8 (CXCL8) are repressed, whereas others, such as IKappaBalpha, are not
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c105 : 1
stoichiometry:c106 : 1
m66*m5*0.1
nodelay
--
0
PMID: 17981503,10542237,14609950 In the case of AP-1, several mechanisms for transrepression by nuclear receptors have been identified, including inhibition of c-Jun N-terminal kinase (JNK) signaling by GR, and direct interaction of PPARalpha with c-Jun, resulting in interference with transcriptional activation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c107 : 1
stoichiometry:c108 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c109 : 1
stoichiometry:c110 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c114 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c119 : 1
stoichiometry:c116 : 1
m68*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c120 : 1
stoichiometry:c118 : 1
m95041*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
m15*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPARgamma ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPARdelta ligand GW0742 worsened the course of colitis in IL-10-deficient mice
p38
p40
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c123 : 1
stoichiometry:c122 : 1
m93487*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c124 : 1
stoichiometry:c125 : 1
stoichiometry:c126 : 1
m5*m70*0.1
nodelay
--
0
PMID: 17981503,11934839 The PPARalpha ligand fenofibrate represses IFNgamma expression in anti-CD3-treated cultured human CD4+ lymphocytes
p42
p42
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c127 : 1
stoichiometry:c132 : 1
stoichiometry:c128 : 1
1.0*0.1
nodelay
--
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c130 : 1
stoichiometry:c131 : 1
m72*m5*0.1
nodelay
--
0
PMID: 17981503,11884448 Similarly, another PPARalpha ligand, Wy14643, represses IFNgamma in activated mouse splenocytes
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c134 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,17631136 More recently, fenofibrate has been shown to repress IL-17 expression in cultured splenocytes activated by PMA plus ionomycin and by Th17 cells in a pathogenic CD4+ T-cell line cultured from C3H Bir mice treated with cecal bacterial antigens
p45
p45
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c139 : 1
stoichiometry:c136 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
p45
p46
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c140 : 1
stoichiometry:c138 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
p45
p47
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c141 : 1
stoichiometry:c137 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m840*0.1
nodelay
--
0
PMID: 17981503,16798734 Interestingly, the proinflammatory cytokine IL-17 induces CXCL8 gene transcription and also stabilizes CXCL8 mRNA via a p38 MAP kinase-dependent pathway
p51
p49
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c155 : 1
stoichiometry:c154 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%. PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11 PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c13 : 1
m16*m17*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPARgamma ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPAR¦Ä ligand GW0742 worsened the course of colitis in IL-10-deficient mice
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c146 : 1
stoichiometry:c147 : 1
m77*m14*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c153 : 1
stoichiometry:c149 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c150 : 1
stoichiometry:c152 : 1
stoichiometry:c151 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c156 : 1
stoichiometry:c158 : 1
stoichiometry:c157 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c160 : 1
stoichiometry:c161 : 1
stoichiometry:c159 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c163 : 1
stoichiometry:c164 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c166 : 1
stoichiometry:c167 : 1
stoichiometry:c165 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c168 : 1
stoichiometry:c170 : 1
stoichiometry:c169 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c173 : 1
stoichiometry:c171 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
p59
p59
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c174 : 1
stoichiometry:c179 : 1
stoichiometry:c175 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,17631136 The PPARalpha ligands fenofibrate and GW7647 also repress CXCL10 mRNA expression and promoter activity in human HT-29 cells, a model for colonic epithelial cells
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c15 : 1
m20*0.1
nodelay
--
0
PMID:17981503,16127449 Repression of lipopolysaccharide (LPS)-induced iNOS (NOS2) gene expression in macrophages has been characterized in detail
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c176 : 1
stoichiometry:c177 : 1
stoichiometry:c178 : 1
m5*m86*0.1
nodelay
--
0
PMID: 17981503,17631136 The PPARalpha ligands fenofibrate and GW7647 also repress CXCL10 mRNA expression and promoter activity in human HT-29 cells, a model for colonic epithelial cells
p61
p61
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c181 : 1
stoichiometry:c182 : 1
stoichiometry:c183 : 1
m69*m4372*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
p51
p62
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c184 : 1
stoichiometry:c185 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11 PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p51
p63
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c187 : 1
stoichiometry:c188 : 1
stoichiometry:c186 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p61
p64
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c189 : 1
stoichiometry:c190 : 1
stoichiometry:c191 : 1
m4372*m89*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
p51
p65
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c193 : 1
stoichiometry:c194 : 1
stoichiometry:c192 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p61
p66
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c195 : 1
stoichiometry:c196 : 1
stoichiometry:c197 : 1
m4372*m92*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c199 : 1
stoichiometry:c198 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503 PPARgamma then represses expression of the inflammatory-response gene Egr-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c201 : 1
stoichiometry:c200 : 1
m94*0.1
nodelay
--
0
PMID: 17981503,16713977 Recently, suppression of the inflammatory response by CO in macrophages has been ascribed to a CO-mediated burst of reactive oxygen species, which induce the expression of PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c202 : 1
stoichiometry:c203 : 1
m95*0.1
nodelay
--
0
PMID: 17981503,16713977 Recently, suppression of the inflammatory response by CO in macrophages has been ascribed to a CO-mediated burst of reactive oxygen species, which induce the expression of PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c17 : 1
stoichiometry:c18 : 1
stoichiometry:c16 : 1
m19*0.1
nodelay
--
0
PMID: 17981503 In the ¡Èoff¡É state, the iNOS gene is actively repressed by a multisubunit complex containing NCoR, histone deacetylase 3 (HDAC3), TBL1, and TBLR1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c204 : 1
stoichiometry:c205 : 1
stoichiometry:c206 : 1
m564*m17*0.1
nodelay
--
0
PMID: 17981503,16943204 Recent studies have demonstrated that PPARdelta binds to ERK5 and is required for ERK5-mediated repression of NF-KappaB
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c14 : 1
stoichiometry:c19 : 1
stoichiometry:c20 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m20*m21*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--